Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cocrystal Pharma ( (COCP) ) just unveiled an announcement.
On October 30, 2025, Cocrystal Pharma announced the completion of a private placement of units priced at-the-market under Nasdaq rules, raising $1.03 million through the sale of 743,024 shares of common stock and unregistered warrants for additional potential proceeds of $1.83 million. The investment, made by company insiders including directors and management, demonstrates confidence in Cocrystal’s mission to advance antiviral therapies and strengthens its financial position as it approaches key clinical milestones.
The most recent analyst rating on (COCP) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Cocrystal Pharma stock, see the COCP Stock Forecast page.
Spark’s Take on COCP Stock
According to Spark, TipRanks’ AI Analyst, COCP is a Underperform.
Cocrystal Pharma faces significant financial challenges, with no revenue and ongoing operational losses severely affecting its stock score. The technical analysis indicates potential downward pressure, while the negative valuation metrics are concerning. However, recent corporate events provide some positive aspects, suggesting future growth potential. Overall, the company’s stock score reflects these mixed factors, indicating substantial risk with some long-term opportunities.
To see Spark’s full report on COCP stock, click here.
More about Cocrystal Pharma
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on developing innovative antiviral treatments for diseases such as influenza, viral gastroenteritis, COVID, and hepatitis. The company utilizes unique structure-based technologies and Nobel Prize-winning expertise to create effective antiviral drugs.
Average Trading Volume: 1,554,816
Technical Sentiment Signal: Sell
Current Market Cap: $13.95M
Find detailed analytics on COCP stock on TipRanks’ Stock Analysis page.